Reagent Generation for Bioanalytical Method Development on Biologics Therapeutics

Open — responses due 30 Nov 2026 (8 days left) · Unrestricted (full and open) · National Institutes of Health (NIH), HHS · Bethesda, MD · NAICS 325411 · Solicitation 75N98027R00020

Get the AI read before you spend a day on this package. FedSift pulls out the deal-breakers and key risks, each quoted from the document. Free, no account.

Analyze this solicitation

Solicitation details

Solicitation number75N98027R00020
Notice ID7bfe3f7284fd49f09f228a6e12e7dc5a
AgencyDepartment of Health and Human Services (HHS)
Sub-agencyNational Institutes of Health (NIH)
Contracting officeNATIONAL INSTITUTES OF HEALTH NIDA
NAICS code325411 — Medicinal and Botanical Manufacturing
Product / service code (PSC)AN11
Set-asideUnrestricted (full and open)
Notice typeSources Sought
Posted16 November 2026
Response deadline30 November 2026
Place of performanceBethesda, MD, USA
CompetitionCompetitive

AI read of this solicitation

Before you spend a day on this package: FedSift reads every document and pulls out what is being bought, the deal-breakers and the key risks — each quoted from the page it came from. Free, no account needed. The result is shared, so the next reader gets it instantly. With a free account it also builds the full compliance matrix.

Track this solicitation

We'll email you if the response deadline moves, an amendment posts, or new documents are added. It closes 30 November 2026. No account needed — one email, unsubscribe in a click.

Description

Title: Reagent Generation for Bioanalytical Method Development on Biologics Therapeutics This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential requirement. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. The Government is especially interested in determining (1) the availability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition (5) commercial product and services availability. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. Background: The Therapeutic Development Branch (TDB) within the Division of Preclinical Innovation (DPI) at National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) conducts translational research in the area of human therapeutics development by moving small molecule and biologic drug candidates forward in the drug development pipeline. Upon reaching predetermined milestones, TDB hands off clinical candidates to external partners to bring these novel therapies to patients. In addition to developing new candidate drugs, TDB seeks to advance the entire field of drug discovery and development by encouraging scientific and technological innovations aimed at improving success rates in the crucial preclinical stage of drug development. The TDB model is to operate as a comprehensive small molecule and biologics drug development organization, moving therapeutic candidates through each phase of the preclinical development process until an Investigational New Drug (IND) application is filed with the US Food and Drug Administration (FDA). TDB conducts drug development as collaborations, with therapeutic candidates originating from academia, industry, non- profit foundations, or internally from NCATS and other NIH Institutes and Centers. TDB’s operational strategy is to combine the capabilities of in-house staff and collaborative partners with complementary support from contract research organizations (CROs). Each development program operates in a multi-disciplinary matrix team environment, with NCATS responsible for the overall planning and execution. Please see the attachment for more details.

Documents in the solicitation package

1 file is attached to this notice.

  • 75N98027R00020_TRND 6 Sources Sought Notice.docx

Download all 1 file as one ZIPFree account, no credit card.

Reading them for requirements? FedSift turns the package into a compliance matrix — every requirement with the page it came from, exportable to Excel.

Or download them one at a time from SAM.gov.

Go deeper on this solicitation

FedSift reads the full solicitation package — every attachment — and pre-extracts the compliance matrix, evaluation factors, key risks, win themes and deal-breakers, each with a verbatim quote and the exact PDF page it came from. It scores the opportunity against your company profile, tells you whether to bid as prime or sub, and ranks teaming partners who could close your gaps.

Open the AI analysis in FedSift →

Free forever plan — no credit card. Browse solicitations without an account; sign in for AI analysis and matching.

Market context: HHS and NAICS 325411

About the buyer and the industry, not this specific solicitation. Source: USASpending.gov award data, updated nightly.

  • In fiscal year 2026, HHS obligated $936K across 3 contract actions under NAICS 325411.
  • 3 contracts worth $1.4M in this category end within the next 18 months.

HHS contracts under NAICS 325411 →

More from Department of Health and Human Services

All HHS solicitations →

Source: this notice on SAM.gov. FedSift republishes public federal procurement data and is not affiliated with the U.S. Government. Always confirm dates and requirements against SAM.gov before responding.

FedSift turns SAM.gov and USASpending data into federal BD intelligence — smart matches, recompete radar, cited AI solicitation analysis and compliance matrices.

Source data: SAM.gov (solicitations) and USASpending.gov (awards), refreshed nightly. FedSift is not affiliated with the U.S. Government.

Pricing · Privacy · Terms · support@fedsift.app